GxP (2)
FDA Increases 'Risk-Based' Drug Manufacturing Inspections & Strengthens Genotoxic Impurity Testing
GxP (2)
4 Ways ICH E6 (R2) 2016 Impacts Good Clinical Practice (GCP)
GxP (2)
5 Ways to Identify the Root Causes of Regulatory Compliance Issues
GxP (2)
3 Parts of a Comprehensive GCP Quality Audit
GxP (2)
New FDA Proposal for Quality Metrics
The FDA Group sets itself apart from traditional consulting firms through its client success and satisfaction rate, and its dedication to the life sciences.
